Seres Therapeutics Files 8-K on Financials
Ticker: MCRB · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
SERES filed an 8-K on March 5, 2024, detailing financial results and operations.
AI Summary
On March 5, 2024, Seres Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations. It also includes information about financial statements and exhibits.
Why It Matters
This 8-K filing provides an update on Seres Therapeutics' financial health and operational results, which is crucial information for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate, significant risks.
Key Players & Entities
- Seres Therapeutics, Inc. (company) — Registrant
- March 5, 2024 (date) — Date of Report
- 001-37465 (company) — Commission File Number
- 27-4326290 (company) — IRS Employer Identification No.
- 101 Cambridgepark Drive Cambridge, MA 02140 (company) — Address of principal executive offices
- (617) 945-9626 (company) — Registrant's telephone number
FAQ
What specific financial statements or exhibits are included in this 8-K filing?
The filing indicates that it includes information regarding 'Financial Statements and Exhibits' but does not list the specific documents within this excerpt.
What is the primary purpose of this 8-K filing for Seres Therapeutics?
The primary purpose is to report on the company's 'Results of Operations and Financial Condition' and to include 'Financial Statements and Exhibits'.
When was this 8-K report filed with the SEC?
The report was filed on March 5, 2024.
What is Seres Therapeutics' Commission File Number?
Seres Therapeutics' Commission File Number is 001-37465.
Where are Seres Therapeutics' principal executive offices located?
Seres Therapeutics' principal executive offices are located at 101 Cambridgepark Drive, Cambridge, MA 02140.
Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-03-05 07:05:53
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar
Filing Documents
- d806486d8k.htm (8-K) — 25KB
- d806486dex991.htm (EX-99.1) — 92KB
- g806486g0305041523662.jpg (GRAPHIC) — 3KB
- 0001193125-24-058584.txt ( ) — 251KB
- mcrb-20240305.xsd (EX-101.SCH) — 3KB
- mcrb-20240305_lab.xml (EX-101.LAB) — 17KB
- mcrb-20240305_pre.xml (EX-101.PRE) — 11KB
- d806486d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following Exhibit 99.1 relates to Item 2.02 and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Seres Therapeutics, Inc. Press Release issued March 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERES THERAPEUTICS, INC. Date: March 5, 2024 By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Chief Legal Officer and Executive Vice President